Preliminary results of the JIKI clinical trial to test the efficacy of favipiravir in reducing mortality in individuals infected by Ebola virus in Guinea.
24.02.2015 - Communiqué
Preliminary data from the JIKI clinical trial, which is testing the efficacy of favipiravir in reducing mortality associated with Ebola, provide two important pieces of information: • absence of efficacy in individuals who arrive at treatment centres with a very high level of viral ...
Foetal growth restriction (FGR): assessment and impact of screening
16.02.2015 - Communiqué
An observational study carried out in France by Jennifer Zeitlin and her team, on over 14,000 women, shows that only 21% of infants with foetal growth restriction (FGR) had been suspected of having FGR during pregnancy. ...
Tous Chercheurs: Experiencing science in order to better understand their disease
11.02.2015 - Communiqué
The 'Tous Chercheurs' association arranges an average of seven practical training courses in biology per year, each one lasting three days, for people affected by chronic diseases ...
Choc Santé (Health Shock): Inserm is releasing a collection of books for the general public.
10.02.2015 - Communiqué
In partnership with Muscadier publishing house, Inserm is creating a series of books to inform the public about health matters. ...
Survival of very premature infants is improving in France: First results of the EPIPAGE 2 study
28.01.2015 - Communiqué
This study is aimed at assessing the survival of infants born between 22 and 34 weeks’ gestation, and their subsequent outcomes. ...
Blood group O associated with a lower risk of developing type 2 diabetes
19.12.2014 - Communiqué
Is there a relationship between blood group and the risk of developing type 2 diabetes? This is the question studied by Guy Fagherazzi and his collaborators from Joint Research Unit 1018, “Centre for Research in Epidemiology and Population Health” (Inserm/University Paris-Sud) at ...